Fig 1.
Antibody selection and adaptation.
A) Comparison of various potential IgG and IgM antibodies for the detection of Taenia antigens. Direct ELISA coated with two-fold serial dilutions of purified T. crassiceps antigen (Tc Ag). Various IgG and IgM antibodies were used for detection and the S/N ratio is shown. TsG10 is the related IgG of TsW5, while 11H12 is the related IgG of TsW11. B) Complete heavy and light chain variable region amino acid sequences used for construction of the TsG10 IgG antibody.
Fig 2.
TsG10-TsG10*bt assay determination of the assay cutoff.
A) Receiver operating characteristic (ROC) curve of the S/N results testing 90 uninfected control serum/plasma/CSF samples and 56 serum/plasma/CSF samples from patients with known active SANCC and a positive antigen result by a comparator assay (see Materials and Methods). B) Using the Wilson/Brown method, while maximizing sensitivity and specificity, the S/N threshold for positivity was chosen to be >2.29 (line shown) plotted alongside the sample S/N results used for ROC curve construction shown in (A). Also shown are the S/N from serum samples from patients with active E. granulosus infection.
Fig 3.
Tc Ag detection of standards using the TsG10 and comparator assays over a dilution series, shown as S/N ratios.
This standard curve was used so that Ts Ag concentrations in patient samples could be interpolated.
Fig 4.
A) Serum, plasma, and CSF samples from patients with known SANCC, but at various stages of treatment (including cured) were tested by the TsG10-TsG10*bt and the comparator assay, ApDia. Both assays were run with the same standard curve and quantitative results interpolated from the standard curve. Data are antigen concentrations +1 (ng/ml). B) Spearman Correlation analysis using the sample results from (A).
Fig 5.
Paired plasma/serum and CSF sample Ts Ag results in active and cured extra-parenchymal NCC (A) Twenty paired plasma/serum and (B) 10 paired CSF samples from patients with active extra-parenchymal NCC during active disease (early in treatment) and at the time of cure. Data are antigen concentrations +1 (ng/ml).
Table 1.
Detection of Ts Ag in the urine by TsG10 assay compared to concurrent TsG10 serum/plasma antigen detection results in patients with extra-parenchymal NCC in various stages of treatment.